PCM
CATX icon

Pointe Capital Management’s Perspective Therapeutics CATX Stock Holding History

Pointe Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,129
Closed -$12.3K – 151
2016
Q4 		$12.3K Buy
+2,129
New +$13K 0.01% 145

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Pointe Capital Management's CATX Position: Q1 2017 in Review

Pointe Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2017, closing a stake of 2,129 shares — an estimated $12.3K sold.

Pointe Capital Management first reported a position in CATX in Q4 2016 and held it in 1 quarter. The position peaked at $12.3K in Q4 2016. 26 funds tracked by Wall St. Rank hold CATX as of Q1 2017.

  • Pointe Capital Management reported no remaining Perspective Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Pointe Capital Management sold 2,129 Perspective Therapeutics shares in Q1 2017, an estimated $12.3K.
  • Pointe Capital Management first reported a position in Perspective Therapeutics in Q4 2016 and held it in 1 quarter.
  • Pointe Capital Management's Perspective Therapeutics position peaked at $12.3K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2017.

Based on Pointe Capital Management's 13F filing for Q1 2017, filed 25 May 2017.